OraSure Applauds $35 Million in CDC Funding to Support Increased HIV Testing and Prevention
04 Giugno 2007 - 12:00PM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics and the manufacturer of the OraQuick ADVANCE�
Rapid HIV-1/2 Antibody Test, today issued a statement in support of
the recent program announcement by the Centers for Disease Control
and Prevention (�CDC�) that it has identified $35 million in
additional funding to expand HIV testing and prevention programs.
These funds are expected to be allocated to specific state and
local jurisdictions by September 30, 2007 for utilization over the
ensuing 12 months. The program announcement, entitled �Expanded and
Integrated HIV Testing for Populations Disproportionately Affected
by HIV, Primarily African Americans,� specifically calls for
proposals from 26 jurisdictions and has a goal of testing an
additional 1.5 million persons in the U.S. for HIV and identifying
20,000 HIV-infected persons who are currently unaware of their
status. These jurisdictions include selected states, cities and
counties that accounted for 95 percent of AIDS cases among blacks
in 2005, according to the CDC. While blacks represent approximately
13 percent of the U.S. population, they account for approximately
half of the more than one million Americans currently estimated to
be living with HIV, and have represented 40 percent of all deaths
among people with AIDS in the U.S. to date, according to the CDC.
In the program announcement, the CDC stated that it expects to
award up to 20 cooperative agreements with funding ranging from a
minimum award of approximately $510,000 to a maximum award of
approximately $6 million. The CDC also stated that the funding is
for a three-year project, with funding in the first year of $35
million provided by the CDC from its 2007 budget and all subsequent
years of funding will be based on future appropriations. The CDC
encouraged applicants to focus at least 80% of their program
activities on expanded and innovative HIV testing activities in
clinical settings. The synopsis and full program announcement can
be viewed at the following URL:
http://www.grants.gov/search/search.do?mode=VIEW&oppId=14227.
�We are extremely pleased that the CDC has identified funding to
expand HIV testing and prevention initiatives for populations
disproportionately affected by HIV, primarily African Americans,�
said Douglas A. Michels, President and Chief Executive Officer of
OraSure Technologies. �Since OraQuick� was first approved in
November 2002, we have been working closely with state and local
jurisdictions to develop and launch innovative and expanded testing
programs. As the manufacturer of the nation�s leading rapid HIV
test, we are committed to continuing our work with both Federal and
local agencies to continue to help identify HIV-infected
individuals and link them into care.� OraQuick ADVANCE� is the
first and only U.S. Food and Drug Administration approved and CLIA
(Clinical Laboratory Improvements Amendments Act of 1988) waived
rapid point-of-care test that can detect antibodies to both HIV-1
and HIV-2 in 20 minutes, using oral fluid, finger-stick or
venipuncture whole blood or plasma specimens. The CDC and the
Substance Abuse and Mental Health Services Administration (SAMHSA)
have effectively deployed over 1 million OraQuick� tests in various
public health, drug treatment and outreach settings throughout the
country.�OraQuick� is also used by hospitals, state departments of
health, clinics, community-based organizations, and
college/university health centers throughout the country. About
OraSure Technologies OraSure Technologies develops, manufactures
and markets oral fluid specimen collection devices using
proprietary oral fluid technologies, diagnostic products including
immunoassays and other in vitro diagnostic tests, and other medical
devices. These products are sold in the United States as well as
internationally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities. In addition,
OraSure sells products for the cryosurgical removal of common and
plantar warts in the over-the-counter or retail market in the
United States, Canada, Mexico, certain European countries,
Australia and New Zealand, and a product for the cryosurgical
removal of common and plantar warts and several other benign skin
lesions to the professional or physician office market in the
United States and many foreign countries. For more information on
the Company, please go to http://www.orasure.com.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024